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Available online 14 April 2016Introduction: Cardiovascular safety assessment requires accurate evaluation of QT interval, which depends on the
length of the cardiac cycle and also on core body temperature (BT). Increases in QT interval duration have been
shown to be associated with decreases in BT in dogs.
Methods: An example of altered QT interval duration associated with changes in body temperature observed
during a 4-week regulatory toxicology study in dogs is presented. Four groups of Beagle dogs received the vehicle
or test item once on Day 1, followed by a 4-week observation period. Electrocardiogram (ECG) parameters were
continuously recorded on Days 1 and 26 by jacketed external telemetry (JET). Core body temperature (BT) was
measuredwith a conventional rectal thermometer at appropriate time-points during the Day 1 recording period.
Results:Decreased BTwas observed approximately 2 h after treatment on Day 1, alongwith increasedQT interval
duration corrected according to the Van de Water formula (QTcV), but the effect was no longer observed after
correction for changes in BT [QTcVcT = QTcV− 14(37.5− BT)] according to the Van der Linde formula. No sig-
niﬁcant changes in QTcV were reported at the end of the observation period, on Day 26.
Discussion: The present study demonstrates that core body (rectal) temperature can easily be monitored at ap-
propriate time-points during JET recording in regulatory toxicology studies in dogs, in order to correct QT interval
duration values for treatment-related changes in BT. The successful application of the Van der Linde formula to
correct QTc prolongation for changes in BT was demonstrated.
© 2016 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/4.0/).Keywords:
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Dog1. Introduction
Cardio-toxicity is a major cause of drug attrition in pre-clinical and
clinical drug development. To detect any potential risk of cardio-
toxicity, safety pharmacology studies use QT interval as a surrogate
marker of proarrhythmic liability (De Ponti, Poluzzi, Cavalli,
Recanatini, & Montanaro, 2002; Couderc & Lopes, 2010), which could
lead to the possible development of fatal arrhythmias, including torsade
de pointes (TdP). Accurate assessment of an effect on repolarisation
requires QT interval correction for changes in heart rate, as QT interval
is dependent on the duration of the cardiac cycle. Therefore a dedicated
formula, the Van de Water formula (QTcV) (Van de Water, Verheyen,
Xhonneux, & Reneman, 1989), is routinely used in dogs.eted external telemetry; ECG,
, Heart rate; QTcV, QT interval
cT, QTcV corrected for changes
ula; SEM, Standard error of the
7005 Evreux, France.
).
. This is an open access article underQT interval, which represents ventricular depolarization and repo-
larization, is not only dependent on cardiac cycle length. Core body
temperature (BT) may also inﬂuence the duration of the repolarisation
period. Decreases in body temperature have been shown to be associat-
ed with increases in QT interval duration, and vice versa, in dogs
(Alhaddad, Khalil, & Brown, 2000; Van der Linde, Van Deuren,
Teisman, Towart, & Gallacher, 2008). Consequently, a correction formu-
la to compensate for changes in BT [QTcVcT = QTcV− 14(37.5− BT)]
was proposed by Van der Linde et al., 2008.
Continuous accurate monitoring of QT interval and core body
temperature is usually performed in fully implanted (telemetry) an-
imals in GLP-compliant stand-alone safety pharmacology studies
(ICH S7A, ICH S7B). This “gold standard” approach for the assess-
ment of a potential adverse effect on cardiovascular function in
non-restrained animals allows simultaneous recording of QT inter-
val and core body temperature.
When cardiovascular assessment is integrated into regulatory toxi-
cology studies involving, for example, candidate drugs, biotechnology-
derived pharmaceuticals (ICH S6) or anticancer drugs (ICH S9), jacketed
external telemetry (JET) is generally considered to be the most ap-
propriate approach. This non-invasive telemetry approach allowsthe CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
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potential effects on QT lengthening in non-restrained animals, but does
not allow accurate assessment of core body temperature as this technol-
ogy is based on measurement of skin temperature.
In the course of our everyday work, we encountered a candidate
drug for which the evaluation of QT increases was complicated by ef-
fects on core body temperature. The identity and mechanism of action
of the drug candidate cannot be disclosed for conﬁdentiality reasons.
In the present study, a 4-week GLP regulatory toxicology study in
dogs, the measurement of rectal temperature to assess core body tem-
perature in restrained animals during cardiovascular safety assessment
via JET is presented as an alternative approach to ensure the evaluation
of key parameters. Electrocardiography recordings andQT intervalmea-
surements were performed by JET technology in freely moving animals,
and rectal temperature was measured with a conventional thermome-
ter under restrained conditions during the recording period at time-
points in accordance with the toxicokinetic proﬁle of the test item. In
this case example, the test item, which had no effect on HERG current,
produced signiﬁcantly increased QTcV with signiﬁcantly decreased
core body temperature on the ﬁrst day of treatment. When QTcV was
corrected for changes in rectal temperature, no signiﬁcant alteration in
QTcVcT was reported, thus demonstrating an application of the QTcV
correction method (Van der Linde et al., 2008).
2. Materials and methods
2.1. Animals
Twenty four healthy Beagle dogs (12 males and 12 females) from
Marshall Farms, North Rose, New York, USA were used in the present
study. At the beginning of the treatment period, the animals were ap-
proximately 7 to 10 months old and had a mean body weight of 9.2 kg
(males; range: 8.3 kg to 10.1 kg) or 6.8 kg (females; range: 5.5 kg to
7.5 kg). During the acclimation period (N3 weeks), the animals were
submitted to hematological, blood biochemistry and veterinary exami-
nations, and were allocated to groups (by sex) using a stratiﬁed ran-
domization procedure.
The animals were housed in pens containing wood shavings (SICSA,
Alfortville, France) for bedding material in a dedicated dog unit (room
temperature: 20 ± 5 °C, relative humidity: 50 ± 30%, light/dark cycle:
12 h/12 h and ventilation≈ 12 cycles/h of ﬁltered, non-recycled air).
The dogs were group-housed in threes (same sex and group) except
during the telemetry recordings, when they were individually housed
in pens located in sound-insulated telemetry rooms containing less
than 4 animals (so that entry into one telemetry roomdid not cause dis-
turbances in the other telemetry rooms). The time spent by technicians
in each telemetry roomwas kept to aminimum to reduce recording dis-
turbances. To avoid contamination, one cage was left empty between
two monitored animals during evaluation.
Animals had free access to tap water, and food was distributed no
sooner than 4 h after treatment.
2.2. Jacketed external telemetry (JET)
The dogs were equipped with a JET system (Data Science Interna-
tional (DSI)) and were monitored using the Ponemah Physiology Plat-
form (DSI) in individual pens situated in small telemetry rooms, with
a limited number of animals (3 to 4) per room.
The animals were habituated to wearing an external telemetry jack-
et on at least two occasions during the pre-treatment period. During the
habituation period, a check for the ECG quality and the presence of ar-
rhythmias was performed for each animal, and the animals were also
habituated to the rectal temperature measurement procedure with a
conventional thermometer under restrained conditions.
The animals were prepared for telemetry recording as follows: The
sites of electrode placement were shaved, cleaned and dried withalcohol. Then ECG electrodes were placed on the thorax of the animal
(lead II conﬁguration) using adhesive patches and protected by an
under-jacket. The ECG electrodes were connected to the telemetry
transmitter, whichwas placed inside the pocket of the jacket. The jacket
was placed over the under-jacket. Jackets were ﬁtted onto the animals
on the day before recording or at least 2 h before administration of the
test item.
ECG signals were digitized and recorded continuously at a sampling
rate of 500 Hz. Data were analyzed using dedicated software (Ponemah
v. 5.0, DSI). All ECG parameters were extracted from the lead II
conﬁguration.
ECG parameters were continuously recorded on Days 1 and 26 by JET.
On Day 1, ECG recordings began no less than 2 h before dose administra-
tion and ended no sooner than 24 h afterwards. On Day 26, the Day 1 ECG
andBT recording timeswere used as time-points, based on the theoretical
treatment time. Heart rate and ECG parameters [PQ, QRS, QT and QTcV
(QT corrected for heart rate according to the Van de Water formula)]
werequantiﬁed in all groupsbefore (meanof themeasurements obtained
at−90,−75 and−60 min) and after (at 0.5, 1, 2, 3, 4, 6, 8, 12, 16 and
24 h) the beginning of the actual or theoretical infusion time.
At each time-point on Days 1 and 26, ten consecutive beats were vi-
sualized and analyzed: heart rate (HR) was measured in beats per min-
ute (bpm), and ECG parameters: PQ interval duration, QRS complex
duration and QT interval duration were measured in milliseconds
(ms). RR interval was also measured, allowing calculation of the
corrected QT interval.
QT interval corrected for changes in HR was calculated according to
the formula of Van deWater (Van deWater et al., 1989): QTcV=QT−
0.087 (60/HR− 1), where QT and QTcV are expressed in milliseconds
andHR in beats/min. QTcVwas corrected for the inﬂuence of BT accord-
ing to the Van der Linde formula (Van der Linde et al., 2008): QTcVcT=
QTcV− 14 × (37.5− BT), where QTcV is expressed in milliseconds and
BT corresponds to the rectal temperature in °C.
2.3. Study design
This study was chosen as it is good example of a regulatory toxicol-
ogy study demonstrating the method for integration of core body tem-
perature over the same period as JET recordings. The identity and
mechanism of action of the drug candidate cannot be disclosed for con-
ﬁdentiality reasons
Four groups of 3 male and 3 female Beagle dogs received a single
intravenous infusion (i.v.) of the test item (TI) at dose-levels of 0
(vehicle), 10, 20 or 30 μg/kg on Day 1, and were then kept for a 4-week
observation period. Treatmentwas performed as a slow (1-minute) intra-
venous bolus under a dosage volume of 0.5 mL/kg.
Rectal temperature was measured on Day 1 using a conventional
thermometer in all groups at 0, 0.5, 2, 4, 12 and 24 h after the actual
or theoretical treatment time. The body temperaturemeasurement pro-
cedure took approximately 1 min. ECG data were collected 5 to 10 min
before body temperature measurement.
Arterial blood pressure was collected immediately after the mea-
surement of rectal temperature, before treatment, then approximately
15 min and 2, 4, 12 and 24 h after treatment, using a high deﬁnition
oscillometry cuff system (data not shown). Blood pressure was mea-
sured over approximately 2–3 min. Dogs had been previously trained
to the procedure and were restrained in order to reduce excitement as
much as possible. Respiratory parameters were recorded using external
telemetry and respiratory inductive plethysmography and a functional
observation battery was performed before treatment then approxi-
mately 4 and 24 h after treatment (data not shown). On Day 1, blood
samples for toxicokinetic were collected from each animal before treat-
ment, at the end of the infusion of the test item, then at 15 min, 30 min,
1, 2, 6 and 24 h after treatment (data not shown). Clinical pathology
data were recorded before treatment (for the inclusion of the animals
in the study) and 24 h after treatments (Day 2).
Table 1
ECG baseline data (mean ± SEM) during the pre-treatment period.
Baseline data
HR QRS PQ QT QTcV QTcVcT BT
(bpm) (ms) (ms) (ms) (ms) (ms) (°C)
Vehicle, 76 ± 4 39 ± 1 97 ± 4 219 ± 5 235 ± 3 253 ± 3 38.7 ± 0.1
TI (10 μg/kg), 80 ± 4 37 ± 1 88 ± 3 215 ± 4 235 ± 2 255 ± 3 38.9 ± 0.1
TI (20 μg/kg), 81 ± 4 40 ± 3 91 ± 2 213 ± 4 233 ± 5 246 ± 7 38.5 ± 0.1
TI (30 μg/kg), 87 ± 7 37 ± 1 88 ± 2 209 ± 6 233 ± 4 249 ± 3 38.6 ± 0.1
TI: test item, n = 6 animals in each group (3 males and 3 females).
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Statistical analysis was performed on the ECG parameters using SAS
software (SAS Institute Inc.). All parameters were expressed as mean±
SEM. Two-way (time and treatment) analysis of variance (ANOVA) for
repeated measurements was performed using SAS PROC MIXED. In
the case of statistical signiﬁcance, additional one-way ANOVA, followed
by a Dunnett test, was implemented at each time point. P values less
than 5% were considered as signiﬁcant.2.5. Regulatory compliance
This investigation was conducted under Good Laboratory Practice
conditions and in compliance with Animal Health regulations, inFig. 1. Heart rate (HR) in vehicle and treated groups on Day 1 and Day 26. Data are expressed
compared to the vehicle group (n = 6 animals: 3 males and 3 females).⁎p b 0.05; ⁎⁎p b 0.01; ⁎particular: Council Directive No. 2010/63/EU of 22 September 2010
on the protection of animals used for scientiﬁc purposes.
3. Results
The test item had no effect on HERG current as 2% HERG inhibition
had been obtained at 100 μM in a GLP manual patch-clamp study
using HEK293 transfected cells (data not shown).
ECG parameters collected during the pre-dose period were homog-
enous in all groups. No statistically signiﬁcant changes were observed
in any of the parameters measured for any of the groups (Table 1),
and no arrhythmias were reported in any of the study animals.
No signiﬁcant changes in arterial blood pressure, respiratory func-
tion or functional observation battery parameters were reported after
treatment with the test item (data not shown).as mean ± SEM. The test item produced dose-dependent increases in HR on Day 1 when
⁎⁎p b 0.001.
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treatment (Day 2) were within the normal baseline range and no sig-
niﬁcant changes in these parameters were observed on Day 2 when
compared to pre-dose values (data not shown). No clinical pathology
data are available for Day 1.
Day 1:
Single intravenous administration of the TI at 10, 20 or 30 μg/kg pro-
duced transient increases in heart rate around 30 min after administra-
tion when compared to the vehicle control group (Fig. 1a and b). No
effects on PQ interval or QRS complex durationwere reported. Increases
in QT (Fig. 2a and b) and QTcV intervals (Fig. 3a and b) were observed
following TI administration. At time-point 2 h after administration of
the vehicle or TI at 10, 20 and 30 μg/kg, respectively, QTcV values
were 227 ± 4, 265 ± 11 (p b 0.05), 285 ± 9 (p b 0.001) and 284 ±
5 ms (p b 0.001).
Statistically signiﬁcant decreases in BT were observed in all treated
animals when compared to the vehicle group (Fig. 4, Table 2). At
time-point 2 h after administration of the vehicle or test item at 10, 20
and 30 μg/kg, respectively, BT was: 38.4 ± 0.1 °C, 36.6 ± 0.4 °C
(p b 0.01), 35.1 ± 0.2 °C (p b 0.001) and 34.1 ± 0.2 °C (p b 0.001).
No arrhythmias and no major changes in J-wave or T-wave ampli-
tude were reported in any of the TI-treated groups.
No effects on QTcVcT interval were observed when QTcV was
corrected for BT according to the Van der Linde formula (Fig. 5). QTcVcTFig. 2.QT in vehicle and treated groups on Day 1 and Day 26. Data are expressed asmean± SEM
vehicle group (n = 6 animals: 3 males and 3 females). ⁎p b 0.05; ⁎⁎p b 0.01.values obtained 2 h after administration of the vehicle or test item at 10,
20 and 30 μg/kg, respectively, were 240 ± 5, 253 ± 9, 252 ± 9 and
236 ± 4 ms.
The relationship between QTcV and BT was linear (y =−12.571x +
718.21) with a negative slope close to 13 ms per degree change in BT
(Fig. 6).
The maximum plasma concentration (Cmax) was reached in all an-
imals at the end of the test item infusion; no signiﬁcant gender differ-
ence was observed (data not shown). The time to reach the highest
plasma test item concentration (Tmax) did not coincide with the max-
imum effect (Emax) observed on body temperature or QT interval
changes (data not shown).
Day 26:
On Day 26, at the end of the observation period, no statistically sig-
niﬁcant changes were observed in HR (Fig. 1a and b), PQ interval and
QRS complex (data not shown), QT interval (Fig. 2a and b) or QTcV
(Fig. 3a and b), when compared to the vehicle control group.
4. Discussion
Physiological changes in body temperature are routinely observed in
human and laboratory animals. Minor changes can be observed in situ-
ations such as when the animals are under stress or during physical ac-
tivities. Greater changes in body temperature may be observed after.. The test itemproduced increases in QT interval duration onDay 1when compared to the
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cological agent.
Body temperature is not routinely monitored in GLP toxicology stud-
ies, despite the fact that alterations in body temperature have been re-
ported in the literature with administration of several pharmacological
agents, such as 5-HT1A receptor agonists (Seletti et al., 1995), dopamine
(Clark, 1979), thyroxine derivatives, cannabinoids, opioid receptor activa-
tors, neurotensins, transient receptor potential vanilloid, adenosine, ade-
nine nucleotides (Zhang et al., 2013), interleukin (Gatti, Beck, Fantuzzi,
Bartfai, & Dinarello, 2002), interferon-alpha (Kentner, Miguelez, James,
& Bielajew, 2006), peptides, amino-acids (Clark, 1979) and hydrogen sul-
phide (H2S) (Zhang et al., 2013).
In stand-alone cardiovascular safety pharmacology studies (ICH S7A
and ICH S7B) involving animals with fully implanted transmitters, core
body temperature and QT interval are measured simultaneously. In
contrast, when cardiovascular safety pharmacology assessments are
integrated into regulatory toxicology studies, a non-invasive JET ap-
proach (Derakhchan, Chui, Stevens, Gu, & Vargas, 2014; El Amrani, El
Amrani-Callens, Loriot, Singh, & Forster, 2015) is used for evaluation of
the effects of drug candidates, such as biotechnology-derived pharma-
ceuticals (ICH S6) or anticancer drugs (ICH S9). While QT-interval can
be monitored continuously and measured accurately in conscious
dogs, the assessment of body temperature using JET technology allowsFig. 3.QTcV in vehicle and treated groups on Day 1 and Day 26. Data are expressed asmean± S
the vehicle group (n = 6 animals: 3 males and 3 females). ⁎p b 0.05; ⁎⁎p b 0.01; ⁎⁎⁎p b 0.001.accurate assessment of skin temperature but not core body temperature
(Akgun et al., 2004). The use of fully implanted telemetry devices in reg-
ulatory toxicology animalsmight be an alternative, but this option is not
yet fully acceptable for at least two reasons: (i) economical: fully im-
planted animals are costly when the number of animals involved in
each study and the cost of the transmitters, surgery and follow-up pro-
cedures are taken into consideration; (ii) possible interaction with the
surgical procedure: clotting, inﬂammation or tissue damagemay some-
times be confounding factors in the toxicological and histopathological
assessment of study data.
Steps should be taken to ensure that the best conditions are main-
tained while using the JET approach in integrated regulatory toxicology
studies. To avoid disturbances during integrated JETmonitoring in regula-
tory toxicology studies, core body temperature is not usuallymeasured, as
during the telemetry recordings for cardiovascular monitoring, access
into the telemetry rooms is usually limited to feeding andphysical checks.
In the present study, we demonstrated howmultiple interventions in the
telemetry room can be conducted when all housing details and practical
problems have been addressed.
Under the experimental conditions of our study, the dogs regained
their normal heart rate within approximately 15 to 20 min after the
technicians left the telemetry rooms (data not shown). When these ob-
servations are taken in consideration, several interventions in telemetryEM. The test item produced dose-dependent increases in QTcV onDay 1 then compared to
Fig. 4.Rectal temperature (mean± SEM). The test item produced dose-dépendent decreases in rectal temperature onDay 1when compared to the vehicle group (n=6 animals: 3males
and 3 females) ⁎⁎p b 0.01; ⁎⁎⁎p b 0.001.
141A.-I. El Amrani et al. / Journal of Pharmacological and Toxicological Methods 81 (2016) 136–143room for body temperature measurement, blood collection or other
clinical examinations could be allowed without prejudice to the telem-
etry recordings in the dogs.
On the ﬁrst day of treatment in the 4-week toxicity study presented in
this report, the test item produced signiﬁcant increases in QT-interval du-
ration andQT corrected for heart rate (QTcV) despite the absence of an ef-
fect on HERG current (data not shown). Rectal temperature measured
within 5 to 10 min after the collection of QT-interval values was consid-
ered to be signiﬁcantly and concomitantly decreased. When QTcV was
corrected for changes in rectal temperature using the Van der Linde for-
mula (Van der Linde et al., 2008), no signiﬁcant alterations in QTcVcT
were reported. At the end of the observation period, 26 days after treat-
ment, no signiﬁcant changes in QT-interval or QTcV were reported.
The range of body temperatures used by Van der Linde et al. (2008)
to produce a QT correction formula for changes in body temperature
was: 37.7 to 34.2 °C in cooled and 37.3 to 42.1 °C in heated anesthetized
dogs. As our investigationwas limited to effects of the test itemonly, the
temperatures recorded in the present study ranged from 33.0 °C to
39.2 °C. We found the relationship between QTcV and BT to be linear,
with a mean average decrease of approximately 13 ms per degree
change in BT. Therefore, even though BT was measured shortly after
the collection of QT interval values, the results were close to those re-
ported by Van der Linde et al. (2008), where a mean average decrease
of 14 ms was observed over a wide range of BT changes. This demon-
strates the robustness of the QTcVcT formula, and shows that it can be
applied to non-anesthetized animals.Table 2
Data collected (mean ± SEM) at the peak effect on BT (2 h post-dosing on Day 1) with maxim
BT
(°C)
QT
(ms
Vehicle 38.4 ± 0.1 219
TI (10 μg/kg)
36.6 ± 0.4⁎⁎
(-4.7%)
259
(1
TI (20 μg/kg)
35.1 ± 0.2⁎⁎⁎
(-8.6%)
265
(2
TI (30 μg/kg)
34.1 ± 0.2⁎⁎⁎
(-11.2%)
265
(2
BT: Body temperature; TI: Test item; n = 6 animals in each group (3 males and 3 females).
⁎ p b 0.05.
⁎⁎ p b 0.01.
⁎⁎⁎ p b 0.001.Our results are in agreement with previous reports demonstrating
that alterations in BT may have a direct effect on QT interval. For
instance, BT decreases produced lengthening of QT-interval (Van der
Linde et al., 2008) independently of any effect on HERG-current. In-
creases in BT may attenuate and decreases in BT may exacerbate any
lengthening of QT interval related to HERG inhibition (Khan, Prasad, &
Glancy, 2010).
The time to reach the highest plasma concentration of the test item
(Tmax) did not coincide with the maximum effect (Emax) observed on
body temperature or QT interval (data not shown). The absence of
coincidence is probably related to themechanismof action andpharma-
cological properties of the test item, which resulted in signiﬁcant de-
creases in body temperature and signiﬁcant increases in QTcV, with
no signiﬁcant changes in PQ interval, QRS complex, arterial blood pres-
sure, respiratory parameters or functional observation battery parame-
ters (data not shown).
Decreases in BT may not, in themselves, have a deleterious effect in
terms of cardiovascular risk despite their effect on QT prolongation. In
the present study, no arrhythmias were reported at any dose-level or
BT. In dogs, lengthening and shortening of QTcV during cooling and
warming, respectively, are not associated with arrhythmias (Van der
Linde et al., 2008).
In therapeutic approaches using clinically controlled therapeutic
hypothermia (e.g. following cardiac arrest, hemorrhagic or ischemic
stroke), hypothermia is considered as beneﬁcial under certain circum-
stances, according to the extent of the decreases in body temperatureum changes vs. vehicle (in %) (n = 6 animals: 3 males and 3 females)
)
QTcV
(ms)
QTcVcT
(ms)
± 8 227 ± 4 240 ± 5
± 14
8%)
265 ± 11⁎
(16%)
253 ± 9
(5.4%)
± 15
1%)
285 ± 9⁎⁎⁎
(25%)
252 ± 9
(5.0 %)
± 9
1%)
284 ± 5⁎⁎⁎
(25%)
236 ± 4
(-1.7 %)
Fig. 5.QTcVcT (mean± SEM) in vehicle and treated groups on Day 1 (QTcV corrected for changes in body temperature).When corrected for changes in body temperature, no effect of the
test item on QT prolongation was observed.
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cooling, intravascular cooling or pharmacological cooling, is considered as
a promising neuroprotective approach against ischemic brain injury
(Zhang et al., 2013), although the mechanism of action underlying this
effect is not yet fully understood. The prolongation of QT-interval during
hypothermia might appear to be a physiological phenomenon without
any pro-arrhythmogenic potential, and this has been clearly shown in
anesthetized swine subjected to mild hypothermia, when increases in
QT interval had no effect on ventricular arrhythmias and therewas no oc-
currence of TdP (Kudlicka et al., 2015).
Despite the beneﬁcial effect of hypothermia, concerns may arise
concerning the pro-arrhythmogenic risk during concomitant effects on
QT prolongation related, on the one hand, to hypothermia and, on the
other hand, to inhibition of the HERG current in patients with inherited
or acquired long QT (Long QT syndrome).
Intravenous infusion of a class III anti-arrhythmic drug, amiodarone,
in a patient subjected to therapeutic hypothermia produced additionalFig. 6. Rectal temperature versus QTcV on Day 1 in individual dogs (n = 24);increases in QTc prolongation, but no life threatening arrhythmia was
reported (Khan et al., 2010). In another case report of congenital Long
QT syndrome, the induction of mild therapeutic hypothermia had no
pro-arrhythmic effect, and no TdP was documented despite greatly
increased QTc interval (Nishiyama, Sato, Aizawa, Nakagawa, & Kanki,
2012).
Further research is needed to evaluate the pro-arrhythmogenic
risk potential of (i) drugs that may have combined effects on BT
and HERG inhibition in healthy animals; (ii) pharmacological agents
that might be associated with the therapeutic hypothermia proce-
dure, especially in patients under medication who might be at risk
during the procedure.
In pre-clinical drug development, and especially during regulatory
toxicology studies, it seems prudent to recommend that the evaluation
of any potential effects of drug candidates on BT should beperformed on
a regular basis, as any such issues should be identiﬁed during the non-
clinical safety assessment. On the other hand, clinicians should be fullyregression analysis showed a linear correlation (y =−12.571x + 718.21).
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changes in body temperature have been previously demonstrated.
Ignoring correction for BT may lead to a misinterpretation of changes
in corrected QT for heart rate in pre-clinical or clinical investigations.
One limitation to BT measurement under restrained conditions may
be difﬁcultly when dealing with non-human primates, unless a long-
term training period is applied. Chemical restraint should not be used
in BT measurement for QT correction, as the chemicals used, e.g. keta-
mine, may have an effect on BT.
5. Conclusion
Wedemonstrated (i) that the QT lengthening observed after admin-
istration of the test item was mainly related to a decrease in core body
temperature, (ii) that core body temperature can easily be monitored
during external telemetry recordings in regulatory toxicology studies
in dogs, and (iii) that the QTcVcT formula (Van der Linde et al., 2008)
can be applied to correct QTcV for changes in body temperature using
measurements obtained with a conventional rectal thermometer in
non-anesthetized dogs.
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